Literature DB >> 21320540

A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets.

Brendan M Giles1, Ted M Ross.   

Abstract

Pandemic outbreaks of influenza are caused by the emergence of a pathogenic and transmissible virus to which the human population is immunologically naïve. Recent outbreaks of highly pathogenic avian influenza (HPAI) of the H5N1 subtype are of particular concern because of the high mortality rate (60% case fatality rate) and novel subtype. In order to develop a vaccine that elicits broadly reactive antibody responses against emerging H5N1 isolates, we utilized a novel antigen design technique termed computationally optimized broadly reactive antigen (COBRA). The COBRA HA sequence was based upon HA amino acid sequences from clade 2 H5N1 human infections and the expressed protein retained the ability to bind the receptor, as well as mediate particle fusion. Non-infectious recombinant VLP vaccines using the COBRA HA were purified from a mammalian expression system. Mice and ferrets vaccinated with COBRA HA H5N1 VLPs had protective levels of HAI antibodies to a representative isolates from each subclade of clade 2. Furthermore, VLP vaccinated animals were completely protected from a lethal challenge of the clade 2.2 H5N1 virus A/Whooper Swan/Mongolia/244/2005. This is the first report describing the use of COBRA-based antigen design. The COBRA HA H5N1 VLP vaccine elicited broadly reactive antibodies and is an effective influenza vaccine against HPAI virus.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21320540      PMCID: PMC3090662          DOI: 10.1016/j.vaccine.2011.01.100

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  62 in total

1.  The influenza virus resource at the National Center for Biotechnology Information.

Authors:  Yiming Bao; Pavel Bolotov; Dmitry Dernovoy; Boris Kiryutin; Leonid Zaslavsky; Tatiana Tatusova; Jim Ostell; David Lipman
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

2.  Identification of the progenitors of Indonesian and Vietnamese avian influenza A (H5N1) viruses from southern China.

Authors:  J Wang; D Vijaykrishna; L Duan; J Bahl; J X Zhang; R G Webster; J S M Peiris; H Chen; Gavin J D Smith; Y Guan
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

3.  Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets.

Authors:  Aleksandr S Lipatov; Erich Hoffmann; Rachelle Salomon; Hui-Ling Yen; Robert G Webster
Journal:  J Infect Dis       Date:  2006-09-12       Impact factor: 5.226

4.  Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.

Authors:  Maria Malm; Erik Rollman; Mart Ustav; Jorma Hinkula; Kai Krohn; Britta Wahren; Vesna Blazevic
Journal:  Viral Immunol       Date:  2005       Impact factor: 2.257

5.  Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.

Authors:  J H C M Kreijtz; R Bodewes; G van Amerongen; T Kuiken; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan
Journal:  Vaccine       Date:  2006-09-07       Impact factor: 3.641

6.  Determination of HIV type 1 CRF01_AE gag p17 and env-V3 consensus sequences for HIV/AIDS vaccine design.

Authors:  Takaichi Hamano; Pathom Sawanpanyalert; Hideki Yanai; Surachai Piyaworawong; Takashi Hara; Sompong Sapsutthipas; Jurairat Phromjai; Shudo Yamazaki; Naoki Yamamoto; Paijit Warachit; Mitsuo Honda; Kazuhiro Matsuo
Journal:  AIDS Res Hum Retroviruses       Date:  2004-03       Impact factor: 2.205

Review 7.  Particle-based vaccines for HIV-1 infection.

Authors:  Kelly R Young; Ted M Ross
Journal:  Curr Drug Targets Infect Disord       Date:  2003-06

8.  Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins.

Authors:  Judy A Mitchell; Thomas D Green; Rick A Bright; Ted M Ross
Journal:  Vaccine       Date:  2003-02-14       Impact factor: 3.641

9.  Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

Authors:  Mary A Hoelscher; Sanjay Garg; Dinesh S Bangari; Jessica A Belser; Xiuhua Lu; Iain Stephenson; Rick A Bright; Jacqueline M Katz; Suresh K Mittal; Suryaprakash Sambhara
Journal:  Lancet       Date:  2006-02-11       Impact factor: 79.321

10.  Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Authors:  Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

View more
  66 in total

1.  Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Authors:  J Brian Kimble; Delphine C Malherbe; Michelle Meyer; Bronwyn M Gunn; Marcus M Karim; Philipp A Ilinykh; Mathieu Iampietro; Khaled S Mohamed; Surendra Negi; Pavlo Gilchuk; Kai Huang; Yuri I Wolf; Werner Braun; James E Crowe; Galit Alter; Alexander Bukreyev
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Authors:  Donald M Carter; Christopher A Darby; Bradford C Lefoley; Corey J Crevar; Timothy Alefantis; Raymond Oomen; Stephen F Anderson; Tod Strugnell; Guadalupe Cortés-Garcia; Thorsten U Vogel; Mark Parrington; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 3.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

4.  A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.

Authors:  Brendan M Giles; Corey J Crevar; Donald M Carter; Stephanie J Bissel; Stacey Schultz-Cherry; Clayton A Wiley; Ted M Ross
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

5.  A combinatorial approach to the design of vaccines.

Authors:  Luis Martínez; Martin Milanič; Leire Legarreta; Paul Medvedev; Iker Malaina; Ildefonso M de la Fuente
Journal:  J Math Biol       Date:  2014-05-25       Impact factor: 2.259

Review 6.  Challenges and future in vaccines, drug development, and immunomodulatory therapy.

Authors:  Heather M Kling; Gerard J Nau; Ted M Ross; Thomas G Evans; Krishnendu Chakraborty; Kerry M Empey; JoAnne L Flynn
Journal:  Ann Am Thorac Soc       Date:  2014-08

7.  Expression and Purification of Virus-like Particles for Vaccination.

Authors:  Maria T Arevalo; Terianne M Wong; Ted M Ross
Journal:  J Vis Exp       Date:  2016-06-02       Impact factor: 1.355

8.  Structural and antigenic characterization of a computationally-optimized H5 hemagglutinin influenza vaccine.

Authors:  Yael Bar-Peled; Jiachen Huang; Ivette A Nuñez; Spencer R Pierce; Jeffrey W Ecker; Ted M Ross; Jarrod J Mousa
Journal:  Vaccine       Date:  2019-08-31       Impact factor: 3.641

Review 9.  Influenza vaccines: challenges and solutions.

Authors:  Katherine Houser; Kanta Subbarao
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

10.  Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.

Authors:  Naoko Uno; Ted M Ross
Journal:  J Virol       Date:  2021-01-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.